The FDA has granted accelerated approval to mirvetuximab soravtansine to treat patients with folate receptor alpha (FRα)–positive, platinum-resistant epithelial ovarian, primary peritoneal, and fallopian tube cancers. The FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx Assay companion diagnostic device, which detects the FRα protein and could determine which patients will likely respond to the antibody–drug conjugate.

You do not currently have access to this content.